Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12336624 | 0.83 | DGAT1 (0.38) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL13087838 | 0.82 | DGAT1 (0.40) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL106943 | 0.82 | DGAT1 (0.40) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL9966137 | 0.79 | DGAT1 (0.41) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL17617164 | 0.76 | CYP4F2 (0.42) | — | |
| SCHEMBL17617200 | 0.76 | CYP4F2 (0.42) | — | |
| SCHEMBL14041111 | 0.76 | DGAT1 (0.39) | DGAT1CA1CA7 | |
| SCHEMBL16938765 | 0.76 | — | — | |
| SCHEMBL15082441 | 0.75 | DGAT1 (0.46) | DGAT1CA12CA1CA7CA14 | |
| SCHEMBL47394 | 0.75 | DGAT1 (0.46) | DGAT1CA12CA1CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | API CORPORATION (JP) | 2016-03-24 | — | — | US | disclosed |
| EP-2423748-A1 | Lithographic printing plate precursor and plate making method thereof | Fujifilm Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083341-A1 | METHOD FOR PRODUCING a-SUBSTITUTED CYSTEINE OR SALT THEREOF OR SYNTHETIC INTERMEDIATE OF a-SUBSTITUTED CYSTEINE | MGMT, GSTA1, CBS | DGAT1 917/4885CA12 454/4885CA1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.